Kestra Medical Technologies, Ltd. (KMTS) Key Metrics
KMTS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.62B
- Enterprise value
- $1.40B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 15.2
- Price / book
- 6.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
KMTS key metrics, FY2020–FY2026
Fiscal year ended April 30, 2026 · U.S. dollarsKMTS valuation Price multiples at each fiscal year-end price.
KMTS returns How much profit the business earns on the capital it uses.
KMTS per-share figures Results divided by the shares outstanding at year-end.
KMTS financial health Debt, liquidity and how easily interest is covered.
KMTS efficiency & capital use Working capital cycle and where the cash goes.
KMTS valuation history
KMTS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KMTS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KMTS cash returned to shareholders
KMTS price vs earnings per share
KMTS key metrics
FY2020–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $1.21B | $1.19B | — | — | — | — |
| Enterprise value | $1.06B | $998.5M | — | — | — | — |
| Price / sales | 12.7 | 19.9 | — | — | — | — |
| Price / book | 4.7 | 5.8 | — | — | — | — |
| EV / sales | 11.1 | 16.7 | — | — | — | — |
| Earnings yield | −10.9% | −9.5% | — | — | — | — |
| Free cash flow yield | −9.6% | −8.5% | — | — | — | — |
| Dividend yield | 0.0% | 0.1% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.3% | 0.1% | — | — | — | — |
| Share price at fiscal year-end | $20.72 | $24.06 | — | — | — | — |
| Per share | ||||||
| Revenue per share | $1.63 | $1.21 | $0.56 | $0.38 | $0.00 | $0.00 |
| Earnings per share | −$2.25 | −$2.30 | −$1.90 | −$4.24 | −$0.69 | −$0.59 |
| Operating cash flow per share | −$1.40 | −$1.57 | −$1.46 | −$3.50 | −$0.60 | −$0.61 |
| Free cash flow per share | −$2.00 | −$2.04 | −$1.71 | −$4.28 | −$0.61 | −$0.62 |
| Cash per share | $3.36 | $4.80 | $0.17 | $0.74 | $0.49 | $0.12 |
| Book value per share | $4.45 | $4.15 | −$4.23 | −$5.91 | $0.04 | $0.08 |
| Tangible book value per share | $4.45 | $4.15 | −$4.23 | −$5.91 | $0.04 | $0.08 |
| Dividends per share | $0.01 | $0.03 | $0.02 | $0.03 | $0.00 | $0.00 |
| Capex per share | $0.60 | $0.48 | $0.25 | $0.78 | $0.01 | $0.00 |
| Debt per share | $0.80 | $0.89 | $0.91 | $1.97 | $0.46 | $0.01 |
| Shares outstanding | 58.4M | 49.5M | 49.5M | 19.9M | 49.5M | 49.5M |
| Change in shares outstanding | +17.9% | 0.0% | +149.1% | −59.9% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −56.6% | — | — | — | — | −764.0% |
| Return on invested capital (ROIC) | −174.3% | — | — | — | — | — |
| Return on assets (ROA) | −40.2% | −66.6% | −222.5% | −243.5% | −177.6% | −374.3% |
| Return on tangible assets | −36.7% | −38.5% | −204.8% | −217.9% | −111.7% | −374.3% |
| Free cash flow margin | −122.6% | −169.2% | −304.7% | — | — | — |
| Financial health | ||||||
| Total debt | $46.8M | $44.3M | $45.2M | $39.1M | $22.8M | $452,000 |
| Cash & short-term investments | $196.4M | $237.6M | $8.2M | $14.8M | $24.3M | $5.8M |
| Net debt | −$149.6M | −$193.3M | $36.9M | $24.3M | −$1.5M | −$5.3M |
| Debt / equity | 0.18 | 0.22 | — | — | 12.94 | 0.12 |
| Debt / assets | 0.13 | 0.15 | 0.98 | 1.01 | 0.75 | 0.06 |
| Current ratio | 4.41 | 6.72 | 0.45 | 0.50 | 3.96 | 1.54 |
| Quick ratio | 4.28 | 6.55 | 0.35 | 0.44 | 3.96 | 1.54 |
| Interest coverage | -17.9 | -13.8 | -13.7 | -14.3 | -28.0 | — |
| Working capital | $172.0M | $217.4M | −$18.1M | −$18.3M | $19.6M | $2.2M |
| Invested capital | $110.0M | $12.1M | −$172.5M | −$93.3M | $273,000 | −$1.4M |
| Tangible asset value | $259.7M | $205.4M | −$209.4M | −$117.6M | $1.8M | $3.9M |
| Net current asset value | $123.6M | $165.0M | −$240.4M | −$137.8M | −$2.6M | $2.2M |
| Graham net-net per share | $1.92 | $3.16 | −$4.92 | −$6.98 | −$0.09 | $0.04 |
| Capital allocation | ||||||
| Dividends paid | $323,000 | $1.7M | $799,000 | $671,000 | $187,000 | $183,000 |
| Share buybacks (net) | $2.8M | — | — | — | — | — |
| Capex / revenue | 36.7% | 39.4% | 45.0% | 202.6% | — | — |
| Capex / depreciation | 4.01 | 2.96 | 1.08 | 3.18 | 0.80 | 0.49 |
| Stock-based compensation / revenue | 35.4% | 40.6% | 5.3% | 15.8% | — | — |
| R&D / revenue | 20.5% | 26.2% | 55.7% | 206.5% | — | — |
| SG&A / revenue | 172.5% | 192.2% | 251.4% | 707.9% | — | — |
| Efficiency | ||||||
| Days sales outstanding | 43.4 | 30.8 | 27.0 | 101.1 | — | — |
| Days of inventory on hand | 52.4 | 50.5 | 35.9 | 42.2 | — | — |
| Days payables outstanding | 202.2 | 245.3 | 199.8 | 78.5 | — | — |
| Cash conversion cycle (days) | -106.4 | -164.0 | -136.9 | 64.8 | — | — |
| Receivables turnover | 8.41 | 11.87 | 13.53 | 3.61 | — | — |
| Payables turnover | 1.81 | 1.49 | 1.83 | 4.65 | — | — |
| Inventory turnover | 6.97 | 7.22 | 10.16 | 8.65 | — | — |
| Asset turnover | 0.29 | 0.35 | 0.66 | 0.22 | 0.00 | 0.00 |
| Average receivables | $11.3M | $5.0M | $2.1M | $2.1M | — | — |
| Average payables | $25.6M | $23.9M | $15.0M | $3.9M | $1.8M | $1.8M |
| Average inventory | $6.6M | $4.9M | $2.7M | $2.1M | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from KMTS's annual financial statements (latest annual report filed July 14, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KMTS valuation and financial ratios
Kestra Medical Technologies earned a return on equity of −56.6% and a return on invested capital of −174.3% in fiscal 2026. It ended the year with $46.8 million of debt and $196.4 million in cash and short-term investments, a net cash position of $149.6 million. It returned $3.1 million to shareholders: $0.3 million in dividends and $2.8 million in share buybacks. The share count rose 17.9% from 49.5M to 58.4M over 5 years.
See the KMTS income statement, the KMTS chart for price history, or the KMTS stock overview for the latest quote and news.
KMTS key metrics FAQ
What is Kestra Medical Technologies's return on equity?
Kestra Medical Technologies's return on equity (ROE) was −56.6% in fiscal 2026: net income of -$131.6 million on average shareholders' equity of $232.5 million.
What is Kestra Medical Technologies's ROIC?
Kestra Medical Technologies's return on invested capital was −174.3% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Kestra Medical Technologies have?
Kestra Medical Technologies had total debt of $46.8 million at the end of fiscal 2026, a debt-to-equity ratio of 0.18 and more cash than debt.
What is Kestra Medical Technologies's dividend yield?
Kestra Medical Technologies paid $0.3 million in dividends in fiscal 2026 ($0.01 per share), a payout ratio of —.
Does Kestra Medical Technologies buy back its shares?
Yes. Kestra Medical Technologies spent $2.8 million on net share repurchases in fiscal 2026 Shares outstanding changed +17.9% over the year, to 58.4M..
What is Kestra Medical Technologies's free cash flow yield?
Kestra Medical Technologies generated -$116.6 million of free cash flow in fiscal 2026, a free cash flow yield of −9.6% on its market value at year-end ($1.2 billion).
What is Kestra Medical Technologies's current ratio?
Kestra Medical Technologies's current ratio was 4.41 at the end of fiscal 2026: current assets were 4.41 times current liabilities.